Page 21234..1020..»

Category : Nanomedicine

Division Biological Engineer Recognized for Research in Nanotechnology – University of Arkansas Newswire

Fred Miller, Division of Agriculture

Jin-Woo Kim uses an atomic force microscope to examine the structures of nano materials.

FAYETTEVILLE, Ark. Really tiny things are a big deal to Jin-Woo Kim. For his work in nanotechnology, he has been named the 2019 Arkansas Biosciences Institute Established Investigator of the Year.

Kim, a professor of biological and agricultural engineering for the University of Arkansas System Division of Agriculture and the University of Arkansas College of Engineering, has spent years developing methods for turning nanoparticles into practical tools for medical, agricultural and manufacturing uses.

Nanoparticles are between 1 and 100 nanometers long, a nanometer being equal to one billionth of a meter.

Kim's research, funded by grants from the National Science Foundation and the National Institute of Health, combines multiple nanoscale materials into single, multifunctional structures with defined physical, chemical or biological characteristics that hold promise for advanced materials and devices. Engineering the shape, size and material compositions influences the useful properties of those materials.

Such materials offer valuable applications for biosensing, biosecurity or nanomedicine, as well as advanced uses in optoelectronics and nanophotonics, Kim said.

"The potential applications of these technologies is wide open," Kim said.

To produce these materials, Kim has been developing nano-building-block technology to guide self-assembly of nanoparticles into specific shapes for specific purposes. He calls it nBlock technology, and it induces nanoparticles to arrange themselves into designed structures.

Now, he is working to expand nBlock technology into more general techniques that can be applied to many different manufacturing designs. He aims to develop a nanotoolbox of assembly methods that are not limited to a single, specific material, but that can be used to produce an unlimited number of different materials.

One of the challenges, Kim said, is scaling up production for manufacturing bulk materials. Self-assembly is a powerful strategy, he said, but the accurate, scalable and high-rate assembly of nanoparticles into specifically designed shapes and sizes is difficult to accomplish.

"Nanotoolbox technology addresses the urgent need for functional, reliable and scalable techniques to fabricate customizable nanostructures for a wide range of uses," Kim said.

In another project, funded by NSF's Center for Advanced Surface Engineering, Kim is developing efficient and sustainable technologies to produce cellulosic nanomaterials from woody biomass.

The raw material is essentially waste from timber industries, Kim said. "A report from the Department of Energy indicates that U.S. forestry operations generate 97 million dry tons of waste annually," he said.

According to the U.S. Department of Agriculture, Arkansas produces 4 million dry tons of waste each year.

"If that abundant and cheap raw material can be sustainably and economically converted into value-added products," Kim said, "it could provide a significant boost to the state's economy."

To investigate the potential of waste biomass for nanomaterial uses, Kim is investigating the impact of genetic and environmental influences on the quantity and quality of nanocellulose. These factors can help identify the most suitable cellulose resources in Arkansas for nanoparticle production, he said.

Kim is combining multiple production processes to identify the most efficient and sustainable methods to fabricate nanocellulose.

In his study of manufacturing processes, Kim said he is targeting both low-cost, high-volume and high-cost, low-volume markets by developing processes with options to synthesize cellulose nanomaterials to different degrees of purity.

Materials with high purity are costly to produce and are suitable for medical or electronic industries. Such products might include drug delivery systems or medical diagnosis agents, smart fabrics, sensing or imaging nanomaterials and other high-end technical uses.

Nanomaterials produced with lower purity at lower cost are suitable for such products as packing materials, filters, some construction materials, microbeads and other uses where high purity is not required.

"USDA estimates that the market size of nanocellulose-enabled products will reach 35 million metric tons per year by 2050," Kim said.

"Developing a viable way to fabricate value-added products from cellulosic nanomaterials could propel Arkansas into a new era of forest bio-based production industries," Kim said. "There's high potential to advance the state's manufacturing, agriculture, forestry and healthcare industries."

To learn more about Division of Agriculture research, visit the Arkansas Agricultural Experiment Station website:https://aaes.uark.edu. Follow us on Twitter at@ArkAgResearchand Instagram atArkAgResearch.

About the Division of Agriculture:The University of Arkansas System Division of Agriculture's mission is to strengthen agriculture, communities, and families by connecting trusted research to the adoption of best practices. Through the Agricultural Experiment Station and the Cooperative Extension Service, the Division of Agriculture conducts research and extension work within the nation's historic land grant education system.

The Division of Agriculture is one of 20 entities within the University of Arkansas System. It has offices in all 75 counties in Arkansas and faculty on five system campuses.

The University of Arkansas System Division of Agriculture offers all its Extension and Research programs to all eligible persons without regard to race, color, sex, gender identity, sexual orientation, national origin, religion, age, disability, marital or veteran status, genetic information, or any other legally protected status, and is an Affirmative Action/Equal Opportunity Employer.

Here is the original post:
Division Biological Engineer Recognized for Research in Nanotechnology - University of Arkansas Newswire

Recommendation and review posted by Alexandra Lee Anderson

Space Shipment Launched With Sports Car Parts, Cookie Oven – The New York Times

A supply ship rocketed toward the International Space Station on Saturday with sports car parts, an oven for baking cookies and a vest to protect against radiation.

Northrop Grumman launched its Cygnus capsule for NASA from Wallops Island, Virginia. The 8,200-pound shipment (3,700 kilograms) should reach the orbiting lab Monday.

"Good launch all the way around," a ground controller observed.

The space station's astronauts will test the oven by baking chocolate chip cookies and try out the new safety vest to gauge its comfort. Both experiments are seen as precursors to moon and Mars journeys.

Other newly arriving equipment will be used in a series of NASA spacewalks later this month to fix a key particle physics detector. Parked outside the space station since 2011, the Alpha Magnetic Spectrometer needs new cooling pumps to continue its search for elusive dark matter and antimatter.

Italy's Lamborghini is also along for the ride. It's sending up samples of carbon fiber used in its sports cars for six months of direct space exposure. Researchers are considering the materials for medical implants.

Like space, the insides of a person's body are an extreme environment, explained Houston Methodist's Alessandro Grattoni, who is collaborating with Lamborghini on the experiment. As a nanomedicine specialist, he said Friday he's continuously on the lookout for new materials for devices that are inserted beneath the skin. These minuscule implants release therapeutic drugs to treat cancer, hormone deficiencies and other illnesses.

Northrop Grumman is now controlling two Cygnus capsules in orbit, a first for the Virginia-based company. Named for the swan constellation, the Cygnus launched last spring is flying free of the 250-mile-high (400-kilometer-high) space station, after completing its grocery run. It will be directed to a fiery re-entry sometime in the near future, taking station trash down with it, according to company officials.

The newest Cygnus is officially called the S.S. Alan Bean after the Apollo 12 astronaut who became the fourth man to walk on the moon 50 years ago this month. He later commanded NASA's first space station, Skylab, and became known for his cosmic-themed paintings. He died last year.

NASA has contracted with Northrop Grumman and SpaceX to keep the space station stocked. This is Northrop Grumman's 12th successful Cygnus flight since 2013. The company has upgraded both its Cygnus and Antares rocket to haul more cargo from NASA's Wallops Flight Facility on the eastern Virginia shore.

The space station is currently home to three Americans, two Russians and one Italian.

Continue reading here:
Space Shipment Launched With Sports Car Parts, Cookie Oven - The New York Times

Recommendation and review posted by Alexandra Lee Anderson

Global Healthcare Nanotechnology (Nanomedicine) Industry Research: Key Companies Profile with Sales, Revenue, Market Share, Price and Competitive…

With the help of 15 chapters spread over 100 pages this report describe Healthcare Nanotechnology (Nanomedicine) Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Healthcare Nanotechnology (Nanomedicine), in 2017 and 2018 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2018 to 2024 is provided in this research report. At last information about Healthcare Nanotechnology (Nanomedicine) sales channel, distributors, traders, dealers, and research findings completes the global Healthcare Nanotechnology (Nanomedicine) market research report.

Access Report Details at:https://www.themarketreports.com/report/global-healthcare-nanotechnology-nanomedicine-market-by-manufacturers-countries-type-and-application-forecast

Market share of global Healthcare Nanotechnology (Nanomedicine) industry is dominate by companies like Abbott Laboratories, Combimatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Mallinckrodt Plc, Merck & Company Inc., Nanosphere Inc., Pfizer, Inc., Celgene Corporation and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2018-2019).

Market Segment by Regions, regional analysis covers:

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia, etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

Biochip

Implant Materials

Medical Textiles

Wound Dressing

Other

Market Segment by Applications, can be divided into

Therapeutic

Diagnostic

Research

Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1503245

Table of Contents

1 Market Overview

2 Manufacturers Profiles

3 Global Healthcare Nanotechnology (Nanomedicine) Market Competitions, by Manufacturer

4 Global Healthcare Nanotechnology (Nanomedicine) Market Analysis by Regions

5 North America Healthcare Nanotechnology (Nanomedicine) by Countries

6 Europe Healthcare Nanotechnology (Nanomedicine) by Countries

7 Asia-Pacific Healthcare Nanotechnology (Nanomedicine) by Countries

8 South America Healthcare Nanotechnology (Nanomedicine) by Countries

9 Middle East and Africa Healthcare Nanotechnology (Nanomedicine) by Countries

10 Global Healthcare Nanotechnology (Nanomedicine) Market Segment by Type

11 Global Healthcare Nanotechnology (Nanomedicine) Market Segment by Application

12 Healthcare Nanotechnology (Nanomedicine) Market Forecast (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1503245

Link:
Global Healthcare Nanotechnology (Nanomedicine) Industry Research: Key Companies Profile with Sales, Revenue, Market Share, Price and Competitive...

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine Market Analysis by Growth, Segmentation, Performance, Competitive Strategies with Top Players Pfizer Inc., CELGENE CORPORATION, Teva…

Nanomedicine Market report has been structured after a thorough study of various key market segments like market size, latest trends, market threats and key drivers which drives the market. This market study report has been prepared with the use of in-depth qualitative analysis of the global market. The report displays a fresh market research study that explores several significant facets related to Nanomedicine Market covering industry environment, segmentation analysis, and competitive landscape. This global market research report is a proven source to gain valuable market insights and take better decisions about the important business strategies.

Industry Analysis:

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Top Dominating Competitors are: Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Nanomedicine Market Report incorporates the precisely contemplated and surveyed information related to the Nanomedicine Market by utilizing various explanatory tools and techniques. The explanatory devices, for example, PEST analysis, Porters five Forces examination, SWOT investigation, speculation return examination and feasibility analysis have been utilized to break down complex Nanomedicine Market data.

Market Drivers and Restraint:

Table of Contents:

Chapter 1 Industry Overview:

Chapter 2 Premium Insights

Chapter 3 Production Market Analysis:

Chapter 4 Major Market Classification:

Chapter 5 Major Application Analysis:

Chapter 6 Industry Chain Analysis:

Chapter 7 Major Manufacturers Analysis:

Chapter 8 New Project Investment Feasibility Analysis:

Chapter 9 Market Driving Factors:

Explore Full Report with Detailed TOC Here at https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Geographical landscape

Have look on the Premium Insights of the Report

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Original post:
Nanomedicine Market Analysis by Growth, Segmentation, Performance, Competitive Strategies with Top Players Pfizer Inc., CELGENE CORPORATION, Teva...

Recommendation and review posted by Alexandra Lee Anderson

Nanovehicles that mimic nature could deliver treatments of the future – ScienceBlog.com

But Prof. Cauda and her colleagues on theTrojaNanoHorse projecthave developed a shell around the crystals so they can slip them past the bodys defences and inside cancer cells.

The idea is to elude the immune system and to elude the barrier of the cell membrane thanks to the biomimetic shell, says Prof. Cauda. In the Trojan horse analogy, the (cancer) cell can be the city of Troy.

Fatty

The tiny shells, which are between 100-200nm or 1,000 times smaller than a human hair, are made from fatty molecules called lipids that form the outer membrane of almost all living cells. In nature, small droplets made from these lipids known as vesicles constantly bud off from the surface of our cells with chemical messages or unwanted materials inside so they can be carried safely to other parts of the body.

Prof. Cauda and her team have tried to copy this by coating their nanocrystals in vesicles produced by cells grown in the lab so they too can pass harmlessly through the body. The surface of the vesicles can also be studded with antibodies against specific cancer cells, helping them to hone in on only the cells they want to kill.

Once a vesicle finds a cancer cell, its antibodies will bind to the surface, allowing the lipids to merge with the cell and releasing the toxic nanocrystal inside. And by growing nanoshells from cells taken from a patients own body, Prof. Cauda believes it will be possible to create personalised treatments that can evade the immune system while still killing cancer cells.

The team have already tested the nanoshell approach against leukaemia cells and cervical cancer in the laboratory. While they hope to be able to perform human trials in the future, Prof. Cauda warned it could still be many years before they reach that stage.

Benefits

If successful, however, this nanomedicine approach could bring benefits compared to traditional chemotherapy treatments by only targeting tumour cells, leaving healthy tissue unaffected and so reducing side-effects.

The nanomedicine approach could offer a site-selective and personalised treatment for the patient, said Prof. Cauda.

In the Trojan horse analogy, the (cancer) cell can be the city of Troy.

Professor Valentina Cauda, Politecnico di Torino, Italy

This approach, however, still largely relies upon the nanoshells chancing upon the cancer cells as they circulate in the patients bloodstream so they can attach to them.

Another team of researchers are working on nano- and micro-machines that might actively be able to improve this by carrying treatments to the site in the body where they are needed.

Dr Larisa Florea, a materials scientist at Trinity College Dublin in Ireland, is leading a project calledChemLifeto create miniature vehicles that can move by themselves in a liquid.

Chemotaxis

The team is attempting to emulate a form of movement known as chemotaxis, which is employed by some basic microorganisms and enables them to move through solutions from low salinity to high salinity, or from acidic to alkaline solutions, for example.

Other research teams in the US have previously shown that man-made droplets can be very preciselynavigated through complex mazeswith this approach. Dr Florea and her colleagues have sought to extend this by using light to control the movement of droplets.

They have created vesicle-like droplets that pair light sensitive molecules with compounds known as surfactants. Surfactants are commonly found in detergents but are also commonly found in many biological systems.

When exposed to light, the photosensitive molecules react by changing their shape, altering the surface tension on each side of the droplet. This causes the molecules in the droplet to flow from one side to the other, driving it forward, a little like the tread of a tank.

The team have shown they can accurately steer dropletsthrough three dimensional spacesandreach speeds of up to 10.4mm per second(0.02mph).

By adding a photoactive material to a droplet, scientists have been able to control its movement in three dimensions through water using light.

If you compare the speed of the movement to the size of these microdroplets, they are faster, pound for pound, than some of the best swimmers in the world, said Dr Florea.

They have also been able to demonstrate that their droplet-shaped vehicles can carry cargo, delivering it to other droplets to trigger a chemical reaction. It raises hopes that similar methods could be used to deliver drugs or other sorts of treatments to specific cells in the body.

While it may be difficult to use light to navigate a drug-carrying droplet through the body, Dr Florea and her colleagues have also explored using mild electrical currents.

Propel

The team have also been developing more complex micromachines that can swim or crawl through liquids like tiny bacteria. Using highly precise 3D printing techniques, they have beenable to create hydrogel structuresaround a few micrometres in size that can contract and expand to propel a structure forward.

We have been making tiny flower-like structures, for example, that can open and close in response to different stimuli, she said. For example it might open at a certain pH and close at another.

This happens because the hydrogels expand by absorbing water and contract by expelling it according to the pH of the surrounding solution.Dr Florea said they hope to also control the movement of hydrogels with changes in temperature or pulses of light.

The ChemLife team are using these hydrogels to create structures with tiny rotating flagella the tiny tail-like appendages that some bacteria use to propel themselves. They are also creating worm-like structures from the same kind of hydrogels that can crawl along surfaces or through liquids.

The ultimate goal is to have these micro-vehicles perform actions like drug delivery or (chemical) sensing, said Dr Florea. But we have to be realistic that this might not be achieved in the near future as the body is a very difficult environment.

The tiny moving structures could also find uses in other ways too. These include delivering chemicals to better improve industrial reactions or creating soft micro-grippers that could be remotely activated to handle delicate components like cells without damaging them.

When you look at what nature can achieve, the opportunities are endless, added Dr Florea.

The research in this article was funded by the EUs European Research Council. If you liked this article, please consider sharing it on social media.

Originally published on Horizon.

More:
Nanovehicles that mimic nature could deliver treatments of the future - ScienceBlog.com

Recommendation and review posted by Alexandra Lee Anderson

MagForce AG Publishes Financial Results for the First Half of 2019 and Operative Highlights – BioSpace

Berlin, Germany and Nevada, USA, October 31, 2019 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the first half of 2019, ending on June 30, 2019, and operative highlights.

During the first half of 2019 we have continued to pass several major milestones and have made significant progress both in the EU with our roll-out strategy and the US with the completion of the first stage in our pivotal clinical US study for the focal ablation of intermediate risk prostate cancer, commented Ben Lipps, CEO of MagForce AG and MagForce USA, Inc. I am steadfast in my belief that by pursuing a strategy of expansion with sustainable partnerships in Europe and providing NanoTherm therapy in the US to patients suffering from prostate cancer, MagForce is well positioned for the future.

Operative Highlights:

Driving forward European roll-out strategy with two additional hospitals offering MagForces NanoTherm therapy for the treatment of brain tumors

In April of 2019, the first hospital outside of Germany, the Independent Public Clinical Hospital No. 4 (SPKS4) in Lublin, Poland, inaugurated its NanoTherm treatment center and is now offering the innovative therapy as an additional treatment option for brain tumor patients from Poland and surrounding countries. The SPSK4 team, led by Prof. Dr. hab. n. med. Tomasz Trojanowski and Prof. Dr. hab. n. med. Radoslaw Rola, have initiated patient treatments for a small Investigator Initiated Trial (IIT) to apply to the Agency for Health Technology Assessment and Tariff System for patient reimbursement of NanoTherm therapy as a supplementary treatment. In addition, private pay treatments with NanoTherm therapy financed by crowd or personal funding are now available. Furthermore, In June, MagForce entered into a cooperation agreement with a further German hospital, the Paracelsus Clinic in Zwickau, where a mobile treatment center has been installed. In the meantime, construction has been completed and, subject to a standard final approval of the competent authority in Germany, the NanoActivator is ready-for-use in the clinic with its renowned neurosurgical team around Prof. Dr. med. habil. Jan-Peter Warnke.

These new cooperations in Germany and Poland cover geographically important regions, and therefore represent another crucial step in MagForces European roll-out strategy. Additionally, the Company continues to see great interest in its therapy from further European countries. In Spain, negotiations with a potential new clinical partner are in an advanced stage, and MagForce is confident to be able to update the market once a cooperation agreement has been successfully concluded. Also, in Italy the Company continues to pursue early stage discussions with specialist clinics.

While a broad geographic coverage to provide greater availability for NanoTherm therapy is at the center of MagForces roll-out strategy, the Company also constantly works to further optimize the therapy and educate medical professionals in its use to provide patients with the best care possible. To this day, 5-years survival rates for patients treated with standard of care have not significantly improved over the last decades and remain very poor at 5 percent. Currently, the best that can be offered applying conventional treatment methods is a modest 14-months overall median survival in patients undergoing maximum safe resection plus adjuvant chemoradiotherapy. Longer survival times are furthermore often limited by a decreased quality of life and to highly selected patient sub-groups with certain favorable prognostic factors. Local tumor ablative treatment modalities, such as NanoTherm therapy, have therefore received increasing interest, as NanoTherm therapy has demonstrated to increase overall median survival to 23.2 months.

In their quest to improve patient care, the neurosurgeons applying NanoTherm therapy for the treatment of brain tumors, continue to find additional strategies to improve efficacy. Prof. Dr. Stummer and his team at the University Hospital of Mnster (UKM) for example, who have been treating brain tumor patients with MagForce's NanoTherm therapy since early 2015, introduced a new nanoparticles application technique called 'NanoPaste' in the clinic in 2016. The method itself and variations thereof are protected by MagForces international patent applications. In previous clinical research, the UKM team demonstrated that a better applicability of heat-focusing nanoparticles around the resection wall after surgical removal of a brain tumor could boost the thermotherapy treatment outcome. In a recent study published in January of 2019 in the Journal of Neuro-Oncology, the team was able to extend the previous findings demonstrating that NanoTherm therapy combined with radiotherapy may result in potent antitumor immune responses leading to long-term stabilization of recurrent GBM patients. The team now plans to further investigate their findings in a prospective study.

MagForce remains committed to providing the highest quality of treatment through ongoing support for physicians. Therefore, the Company announced its newly launched NanoTherm Therapy School in January. NanoTherm Therapy School offers a comprehensive application training series, developed in close collaboration with leading experts in the application of the MagForces therapy and consists of three consecutive modules to certify surgeons in the use of its innovative NanoTherm technology: Module A The Basics; Module B Advanced Course Stereotactic Instillation; and Module C Interaction with New Neurosurgical Techniques. The first session, Module A, took place at the end of January 2019, and was met with great excitement from participants. Building on this success, Module B will be held in Berlin on November 14 and 15. On the Companys website, you will find the program and registration details for the next module in November.

Pivotal US study for a unique focal prostate cancer treatment option completed stage 1; preparations for next study stage initiated

In the US, prostate cancer, is one of the most frequently diagnosed forms of cancer. Fortunately, prostate cancer is treatable, if detected early. Still, there remains an important unmet need for patients who have progressed to the medium-risk stage and for whom the benefits of treatment with current methods come with a significant risk of related side effects. NanoTherm therapy has the potential to significantly change the way prostate cancer is treated, as it allows for a less invasive, less aggressive treatment modality that could cure the cancer or, at a minimum, reduce a patients chances of needing a more aggressive treatment in the future.

The MagForce US pivotal clinical study in the indication of prostate cancer continues to progress well and the Company announced the completion of enrollment, treatment, and the analysis of the results of this first stage. During Stage 1, MagForce USA worked diligently with study investigators, medical technicians and patients, to not only successfully develop a standardized clinical procedure but also demonstrated a favorable safety and tolerability profile.

In summary, Stage 1 of the study has shown the following important successes: Firstly, validation of standardized clinical procedure; secondly, initial findings in this cohort show only minimal treatment-related side effects, which were tolerable and similar to those commonly associated with biopsies; and thirdly, the ablation analysis showed very well defined ablation and cell death in the region of the nanoparticle deposit as we observed with the previous pre-clinical results.

The Stage 1 ablation results also confirm the observations of Knavel and Brace in 2013 that from 42 C to 46 C, irreversible damage occurs, and after 10 minutes, significant necrosis occurs. From 46 C to 52 C, the time to cell death decreases owing to a combination of microvascular thrombosis, ischemia, and hypoxia. By heating from the inside out, as done with focal ablation using the NanoTherm therapy system, minimization of side effects can be achieved. With the encouraging results from Stage 1, MagForce is optimistic that the Company will also be able to successfully manage the treatments in the next stage of the clinical trial. With the high interest in enrollment received from prostate cancer patients and their attending physicians, MagForce is confident to be able to successfully enroll the required number of prostate cancer patients for the last stage of the study.

Results of operations, net assets and financial position

Revenues for the reporting period amounted to EUR 26 thousand compared to EUR 24 thousand in the previous year and resulted mainly from commercial treatments of patients with NanoTherm therapy.

Other operating income amounted to EUR 329 thousand (previous year: EUR 9,199 thousand). The high other operating income in the previous year is attributable to the transfer of shares in MagForce USA, Inc., between group companies, realizing hidden reserves in the amount of EUR 8,769 thousand.

The cost of materials decreased from EUR 364 thousand to EUR 194 thousand which was due in particular to the reduction in expenses for purchased services for the NanoActivators.

Personnel expenses increased to EUR 1,846 thousand (previous year: EUR 1,729 thousand) primarily resulting from the addition of employees in the second half of 2018. Other operating expenses remained at the level of the previous year at EUR 1,608 thousand (previous year: EUR 1,527 thousand).

Consequently, the operating result for the first half of 2019 was negative at EUR 3,610 thousand, whereas the previous year ended with a positive operating result of EUR 5,305 thousand due to the transfer of the shares in MagForce USA, Inc., within the group.

In total, the Company generated a net loss for the period of EUR 4,912 thousand (previous year: net profit of EUR 4,106 thousand)

Cash flows from operating activities amounted to EUR -2,856 thousand (previous year: EUR - 4,009 thousand). The cash outflow from operating activities was derived indirectly from the net loss for the period.

The cash outflows from investing activities amounted to EUR -785 thousand (previous year: EUR - 516 thousand) and related primarily to the contributions made in the reporting period to provide financial support for the subsidiary MT MedTech Engineering GmbH and the completion of the mobile NanoActivator therapy center in Lublin, Poland, as well as the construction of a new mobile NanoActivator therapy center in Zwickau, Germany.

The cash flows from financing activities amounted to EUR 3,325 thousand (previous year: EUR 9,189 thousand) and is mainly attributable to the proceeds from the capital increase from Authorized Capital.

At the end of the reporting period, cash and cash equivalents amounted to EUR 1,178 thousand (December 31, 2018: EUR 1,494 thousand).

Financing transactions of the Company

To improve liquidity and to accelerate the on-going international expansion, the Company executed the following financing measure during the first half of the year.

In June, MagForce AG successfully resolved and completed a capital increase from authorized capital. By issuing 1,176,472 new no-par value bearer shares at a price of EUR 4.25 per share under exclusion of the shareholders' statutory subscription rights, the financing measure has a total volume of EUR 5 million, of which the Company received EUR 1.8 million after the reporting date on July 2, 2019.

The additional capital will primarily be used to accelerate the on-going international expansion of MagForce, in particular in Europe. Based on the highly satisfying treatment results, MagForce expects the European roll-out, combined with reimbursement approval in relevant countries, will significantly speed up revenue generation and profitability of the European business.

Outlook and financial prognosis 2019 and beyond

The outlook for the year 2019, as reported in the 2018 annual report, published on June 20, 2019 was reaffirmed by management.

About MagForce AG and MagForce USA, Inc.MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm, NanoPlan, and NanoActivator are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.comGet to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

DisclaimerThis release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

- End of press release -

Read more:
MagForce AG Publishes Financial Results for the First Half of 2019 and Operative Highlights - BioSpace

Recommendation and review posted by Alexandra Lee Anderson

Doheny and UCLA Stein Eye Institutes Welcome Kaustabh Ghosh, PhD, to the Scientific and Clinical Research Faculty – P&T Community

LOS ANGELES, Oct. 31, 2019 /PRNewswire/ --Doheny and UCLA Stein Eye Institutes proudly welcome Kaustabh Ghosh, PhD, to the scientific faculty as Associate Professor in basic science at the UCLA David Geffen School of Medicine. Dr. Ghosh is distinguished as an interdisciplinary researcher with expertise in the fields of vascular inflammation, mechanobiology, bioengineering, and nanomedicine.

"I am tremendously proud and honored to begin this position at Doheny-UCLA," says Dr. Ghosh. "I entered the field of biomedical research from an engineering background, which perhaps gave me a new perspective to see things differently. As a biomedical engineer, it allowed me to think about diseases in a way that a typical biomedical researcher and clinician may not."

Dr. Ghosh states that also as a vascular biologist, one such perspective he was able to successfully introduce was the importance of "stiffness" of blood vessels in disease pathogenesis.

"Doheny will be the ideal place for me to realize the true translational potential for my work as it offers strength and resources in ophthalmic imaging," shares Dr. Ghosh. "Doheny also provides the perfect balance between basic science and clinical research."

He adds, "I look forward to developing strong, collaborative relationships with members of Doheny-UCLA engineering, biomedical sciences and clinical infrastructure. Our goal will be to discover effective treatment strategies from a multidisciplinary approach especially in the area of investigating the role of chronic vascular inflammation, a major determinant of various debilitating conditions including macular degeneration and diabetic retinopathy."

Dr. Ghosh was most recently Associate Professor of Bioengineering at University of California, Riverside (UCR) as well as Participating Faculty in the Division of Biomedical Sciences, Stem Cell Center and the Program in Cell, Molecular and Developmental Biology. The Ghosh Research Group at UCR focused on leveraging the principles of mechanobiology to examine and treat inflammationmediated vascular degeneration associated with diabetic retinopathy and agerelated macular degeneration, the leading causes of vision loss in the diabetic and aging population. In 2016, these studies were supported by two R01 grants from the National Eye Institute (NEI), and a macular degeneration grant from the BrightFocus Foundation. Dr. Ghosh has received numerous awards during his research career, including the Hellman Fellowship and the NIH Postdoctoral Training Grant, and has published 24 peer-reviewed papers in highly-regarded journals that include PNAS, The FASEB Journal, Science, and Nano Letters, among others.

In 2011, prior to joining UCR, Dr. Ghosh was a postdoctoral fellow in the laboratory of Donald Ingber, MD, PhD, part of the Vascular Biology Program at Boston Children's Hospital and Harvard Medical School. In 2006, Dr. Ghosh received his PhD in Biomedical Engineering from Stony Brook University, New York. He obtained his undergraduate degree in Chemical Engineering from National Institute of Technology, Warangal, India in 2001.

Dr. Ghosh's dedication to collaborative research and team building is evident in his numerous and illustrious achievements. His distinguished scientific leadership demonstrates an excellence that will contribute greatly to Doheny Eye Institute's research programs.

About Doheny Eye InstituteFor over 70 years, Doheny Eye Institute has been at the forefront of vision science. From seeking new ways to free blockages that prevent fluid drainage in glaucoma, to replacing retinal cells in age-related macular degeneration, to providing colleagues worldwide with standardized analyses of anatomical changes in the eyes of patients, Doheny clinicianscientists and researchers are changing how people see and also how they think about the future of vision. Please visit doheny.org for more information.

Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best inpatient care, vision research and education. This affiliation combines the strength, reputation and distinction of two of the nation's top eye institutions to advance vision research, education and patient care in Southern California.

CONTACT INFORMATIONMedia Contact:Matthew RabinDirect: (323) 342-7101Email: mrabin@doheny.org

View original content to download multimedia:http://www.prnewswire.com/news-releases/doheny-and-ucla-stein-eye-institutes-welcome-kaustabh-ghosh-phd-to-the-scientific-and-clinical-research-faculty-300949566.html

SOURCE Doheny Eye Institute

More here:
Doheny and UCLA Stein Eye Institutes Welcome Kaustabh Ghosh, PhD, to the Scientific and Clinical Research Faculty - P&T Community

Recommendation and review posted by Alexandra Lee Anderson

Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars – P&T Community

PALM BEACH, Florida, Oct. 29, 2019 /PRNewswire/ -- There is much activity in the nanotechnology & nanomedicine markets as new treatments and human clinical trials are growing at a record pace. And these new treatment are hope they could be key to combating viral infections such as, bacteria, viruses, fungi,HBV, hepatitis C, Influenza, HSV, Human papillomavirus and parasites account for approximately 15million deaths worldwide, with acute respiratory infections and human immunodeficiency virus (HIV) being the leading causes. The National Institutes for Health NCBI Center for Biotechnology Information (NCBI) reports: "Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery." Mentioned in today's commentary includes: TG Therapeutics, Inc. (NASDAQ: TGTX), NanoViricides, Inc. (NYSE: NNVC), Matinas BioPharma Holdings, Inc. (NYSE: MTNB), Clovis Oncology, Inc. (NASDAQ: CLVS), Pfizer Inc. (NYSE: PFE).

Nanoparticle-based delivery systems present new opportunities to overcome challenges associated with conventional drug therapies and have therefore attracted enormous interest in the treatment of viral infections. Nanomaterials can be engineered to incorporate conventional antiviral properties with those modifications that are unique to nanosystems (ultra small and controllable size, large surface area to volume ratio, and the ability to tailor the surface with the possibility of multi-functionalization). This is undoubtedly a promising tool for biomedical research and clinical use.

One of the more active companies in the industry includes NanoViricides, Inc. (NYSE American: NNVC). NanoViricides,a leader in nanomedicines with novel platform technology to treat difficult and life-threatening viral diseases, on October 9, 2019 announced that it has initiated bio-analytical studies as part of the required IND-enabling preclinical safety and toxicology studies of NV-HHV-101, moving towards human clinical trials.

The Company has contracted NorthEast BioLab, Hamden CT, to conduct the bio-analytical studies and facilitate the toxicokinetic analyses. These studies and analyses are part of the required general safety and toxicology studies that will go into an Investigational New Drug (IND) Application to the US FDA.

NorthEast BioLab has already performed the bio-analytical assay development and validation and is in the process of determining the concentrations of NV-HHV-101 in blood samples from the general safety and toxicology studies that are required for IND.

The company feels that the market size for its immediate target drugs in the HerpeCide program is variously estimated into Billions to tens of Billions of Dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

NanoViricidesalso released a report this past August that its first drug candidate, NV-HHV-101, is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company reports that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.

The Company has previously found that NV-HHV-101 was safe and well tolerated in non-GLP safety/toxicology studies. The GLP studies are an expanded version of the non-GLP studies, with extended treatment, larger number of subjects, and stringent operational requirements as specified by the current Good Laboratory Practices guidelines for such studies.

Additional studies required for the Safety and Toxicology datasets for filing an IND are in progress.

The Company anticipates advancing NV-HHV-101 into human clinical trials for topical dermal treatment of the shingles rash as the initial indication, assuming that these studies are successful. The Company also continues to evaluate this broad-spectrum drug candidate as well as certain variations based on the same candidate, for the treatment of other herpesviruses, namely HSV-1 cold sores and HSV-2 genital herpes. The market size for its immediate target drugs in the HerpeCide program is variously estimated into billions to tens of billions of dollars. The Company believes that its dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials. The Company believes that additional topical treatment candidates in the HerpeCide program, namely, HSV-1 "cold sores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enabling development and then into human clinical trials.

In addition, the Company also recently announced that its first clinical drug candidate, NV-HHV-101, for the treatment of the Shingles virus (aka VZV), is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company has reported that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment.

NanoViricides' current programs target a potential market opportunity of over $20 Billion. Investors are urged to view an informative video interview with Anil R. Diwan, PhD, President and Executive Chairman, who was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London. Click here to access the video interview.

In other biotech news in the markets this week:

TG Therapeutics, Inc.(NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, announced that the follicular lymphoma (FL) cohort of the UNITY-NHL Phase 2b pivotal trial evaluating single agent umbralisib, the Company's novel, once daily, PI3K delta inhibitor, met the primary endpoint of overall response rate (ORR) as determined by Independent Review Committee (IRC) for all treated patients (n=118) who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent. The results met the Company's prespecified ORR target of 40-50%. Importantly, umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports.

The Company plans to present the data at a future medical conference as well as discuss the data with the U.S. Food and Drug Administration (FDA).

Matinas BioPharma Holdings, Inc.(NYSE AMER: MTNB), a clinical stage biopharmaceutical company, this month announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

"We are extremely pleased to advance clinical development of MAT2203 for the treatment of cryptococcal meningitis," commented Theresa Matkovits, Ph.D., Chief Development Officer of Matinas.

Clovis Oncology, Inc.(NASDAQ: CLVS) this month announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement.

"Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting," said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer.

Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2019 and updated certain components of its 2019 financial guidance.Third-Quarter 2019 Revenues of $12.7 Billion, Reflecting 3% Operational Decline; Excluding the Impact from Consumer Healthcare, Third-Quarter 2019 Revenues were Flat Operationally - See the full financial reporting at: https://finance.yahoo.com/news/pfizer-reports-third-quarter-2019-104500229.html

DISCLAIMER:FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein.FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers.Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc.by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:editor@financialnewsmedia.com -+1(561)325-8757

The rest is here:
Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars - P&T Community

Recommendation and review posted by Alexandra Lee Anderson

Comprehensive Study on Healthcare Nanotechnology (Nanomedicine) Market 2019 | Trends, Drivers, Strategies, Applications and Competitive Landscape…

New report on Healthcare Nanotechnology (Nanomedicine) Market 2019 focuses on the growth opportunities, which will help the Healthcare Nanotechnology (Nanomedicine) market to expand operations in the existing markets. Healthcare Nanotechnology (Nanomedicine) market research study is significant for manufacturers in the Healthcare Nanotechnology (Nanomedicine) market, including industry stakeholders, distributors, suppliers, and investors, and it can also help them understand applicable strategies to grow in the Healthcare Nanotechnology (Nanomedicine) market.

In Healthcare Nanotechnology (Nanomedicine) Market Report, Following Companies Are Covered:

Healthcare Nanotechnology (Nanomedicine) Market Report Provides Comprehensive Analysis of:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14099195

Key Market Trends:

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.

Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.

North America is Expected to Hold the Largest Share in the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.

Reasons for Buying Healthcare Nanotechnology (Nanomedicine) Market Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14099195

Detailed TOC of Healthcare Nanotechnology (Nanomedicine) Market Report 2019-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures4.2.3 Growing Preference for Personalized Medicines4.3 Market Restraints4.3.1 High Cost4.3.2 Stringent Regulations for Commercial Introduction4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Application5.1.1 Drug Delivery5.1.2 Biomaterials5.1.3 Active Implants5.1.4 Diagnostic Imaging5.1.5 Tissue Regeneration5.1.6 Other Applications5.2 By Disease5.2.1 Cardiovascular Diseases5.2.2 Oncological Diseases5.2.3 Neurological Diseases5.2.4 Orthopedic Diseases5.2.5 Infectious Diseases5.2.6 Other Diseases5.3 Geography5.3.1 North America5.3.1.1 US5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 France5.3.2.2 Germany5.3.2.3 UK5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle East & Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle East & Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Sanofi SA6.1.2 Celegene Corporation6.1.3 CytImmune Sciences Inc.6.1.4 Johnson & Johnson6.1.5 Luminex Corporation6.1.6 Merck & Co. Inc.6.1.7 Nanobiotix6.1.8 Pfizer Inc.6.1.9 Starpharma Holdings Limited6.1.10 Taiwan Liposome Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Superphosphate Market 2019 Global Industry Share, Size, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2023

Infusion Pump Market Segmentation 2019-2023 Covers Price, Sales, Revenue, Growth Rate Details by Regions, Types, and Applications

Global Nut Meals Market 2019-2022 Segmentation Based on Product, Application and Region

Global Silicon Wafers Market 2019 Global Industry Size, Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2025

Link:
Comprehensive Study on Healthcare Nanotechnology (Nanomedicine) Market 2019 | Trends, Drivers, Strategies, Applications and Competitive Landscape...

Recommendation and review posted by Alexandra Lee Anderson

Advances in nanomedicine for the treatment of ankylosing spondylitis | IJN – Dove Medical Press

Yanhai Xi,1,* Tingwang Jiang,2,* Birendra Chaurasiya,3 Yanyan Zhou,1 Jiangmin Yu,1 Jiankun Wen,1 Yan Shen,3 Xiaojian Ye,1 Thomas J Webster4

1Department of Spine Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, Peoples Republic of China; 2Department of Immunology and Microbiology, Institution of Laboratory Medicine of Changshu, Changshu, Jiangsu 215500, Peoples Republic of China; 3Department of Pharmaceutics, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, China Pharmaceutical University, Nanjing, Peoples Republic of China; 4Department of Chemical Engineering, Northeastern University, Boston, MA, USA

*These authors contributed equally to this work

Correspondence: Xiaojian YeDepartment of Spine Surgery, Changzheng Hospital, Second Military Medical University, 360 Huntington Avenue, Shanghai, MA 200003, Peoples Republic of ChinaTel +86 1 381 734 6934Email xjyespine@smmu.edu.cn

Thomas J WebsterDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USATel +1 617 373 6585Email th.webster@neu.edu

Abstract: Ankylosing spondylitis (AS) is a complex disease characterized by inflammation and ankylosis primarily at the cartilagebone interface. The disease is more common in young males and risk factors include both genetic and environmental. While the pathogenesis of AS is not completely understood, it is thought to be an immune-mediated disease involving inflammatory cellular infiltrates, and human leukocyte antigen-B27. Currently, there is no specific diagnostic technique available for this disease; therefore conventional diagnostic approaches such as clinical symptoms, laboratory tests and imaging techniques are used. There are various review papers that have been published on conventional treatment approaches, and in this review work, we focus on the more promising nanomedicine-based treatment modalities to move this field forward.

Keywords: ankylosing spondylitis, pathogenesis, genetic factors, environmental factors, treatment approaches

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read this article:
Advances in nanomedicine for the treatment of ankylosing spondylitis | IJN - Dove Medical Press

Recommendation and review posted by Alexandra Lee Anderson


Page 21234..1020..»